Updated results of a phase 1 study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M Meeting Abstract
| Authors: | Tan, D. S. W.; Yang, J. C. H.; Leighl, N. B.; Riely, G. J.; Sequist, L. V.; Felip, E.; Seto, T.; Wolf, J.; Moody, S. E.; Adams, K.; Schmitz, S. F. H.; Tan, E. Y.; Kim, D. W. |
| Abstract Title: | Updated results of a phase 1 study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 467s |
| Language: | English |
| ACCESSION: | WOS:000404711506192 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.9044 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 9044 -- Source: Wos |
